ORIC Pharmaceuticals stock target holds at $21 by H.C. Wainwright
H.C. Wainwright research firm maintained a positive outlook on ORIC Pharmaceuticals (NASDAQ:ORIC), reiterating a Buy rating and a $21.00 price target for the company's stock. Currently trading at $11.
ORIC Pharmaceuticals shares surge on potential data leak
ORIC Pharmaceuticals Inc. (NASDAQ: ORIC) shares rose 12% following a recommendation from Cantor Fitzgerald to buy shares amid ...
Guggenheim Reiterates “Buy” Rating for ORIC Pharmaceuticals (NASDAQ:ORIC)
ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Guggenheim in a research report issued to clients and investors on Monday,Benzinga reports.
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC) and Biogen (BIIB)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oric Pharmaceuticals (ORIC – Research Report) ...
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Inmune Bio (INMB) and Vertex Pharmaceuticals (VRTX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Oric Pharmaceuticals (ORIC – Research ...
Yahoo Finance6d
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing ...